NAI (Nogapendekin Alfa Inbakicept) Plus Standard of Care in Critically Ill Adults With Sepsis
← catalyst calendarNCT07783789 · readout in 412 d
Sponsored by ImmunityBio, Inc. (industry) · IBRX — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
49estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-25
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-15 | estimated | When the study began enrolling |
| Primary completion | 2027-10-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-13 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sepsis
- Septic Shock
Intervention
- Drug: Nogapendekin alfa inbakicept (NAI) — also filed as N-803, ANKTIVA
Primary outcome
what the primary-completion date above is the date OF28-Day Survival Rate
measured From Day 1 (first NAI dose) through Day 28
Related
IBRX's other studiesmost recently updated first
- A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia Phase 1 · Terminated
- Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In Phase 3 · Recruiting
- Study for Participants With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1 · Active, not recruiting
- N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma Phase 2 · Active, not recruiting
- A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer Phase 2 · Recruiting
Permalink · IBRX's whole pipeline · Catalyst calendar · Every registered study · What changed